SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

NANOVEU LIMITED(NVU)

Click here for free access to this company's:
ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 

Shareholder links

Our website ranking of NVU: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Registry Services LEVEL 2, 267 St Georges Terrace,, PERTH, WA, AUSTRALIA, 6000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000024796
Address: 1/18 Olive Street, Subiaco WA 6008, Australia
Tel:  +61 8 6244 9095 Fax: 

Date first listed: 30/11/2018
Company Secretary: Michael van Uffelen
Sector: Technology Hardware & Equipment Industry Group: 
Activities: Technology company that shapes vision through the power of modern and cutting-edge nanotechnology. Nano imprint science is applied to deliver vision-based applications

News & Events

Expand this box to read and print

OFX Transferring Money Internationally to Free

The suspension of trading in the securities of Nanoveu Limited will be lifted from the commencement of trading on Friday, 14 August 2020, following the release by NVU of an announcement regarding a capital raising.

14/08/2020

The company releases a notice of Proposed issue of Securities - NVU.

14/08/2020

Nanoveu has secured an up to $2,400,000 investment by Antiviral Technologies Portfolio, LLC, a US based specialist institutional investor. An initial investment of $600,000 on execution. An additional $1,000,000 to be invested subject to shareholders' approval ($400,000 at the Investor's election). A further $800,000 may be invested by mutual consent of both parties subject to shareholders' approval. Funds will strengthen Nanoveu's balance sheet ahead of launch of new business lines including antiviral screen protector technology and laminating machines.

14/08/2020

The securities of Nanoveu Limited will be suspended from quotation from the commencement of normal trading on Friday, 7 August 2020 under Listing Rule 17.2, at the request of NVU, pending the release of an announcement regarding a capital raising.

06/08/2020

The suspension of trading in the securities of Nanoveu Limited will be lifted immediately following the release by NVU of an announcement regarding a new product.

15/04/2020

Nanoveu to incorporate antiviral nanotechnology into smartphone and tablet protective screens and cases, targeting late Q2 / early Q3 2020 product availability. Initial testing on the top layer of Nanoveu's planned products has demonstrated Nanoveu's technology to be effective against viruses and bacteria "“ including influenza A (subtype H3N2) and E. coli. Independent laboratories in the USA and Singapore have been engaged to conduct testing on prototypes for the human coronavirus OC43 (HCoV-OC43) (a betacoronavirus), which is the same genus as SARS-CoV-2 (the virus that causes COVID-19). Procurement for the first production run of smartphone protective screens is underway. Nanoveu's antiviral nanotechnology is considerably improved upon compared to existing anti-bacterial smartphone protective screens and cases which do not protect against viruses. Nanoveu is investigating pathways to market with potential for pre-orders in parallel with product development and production, targeting products being available in late Q2 2020 / early Q3 2020.

15/04/2020

The securities of Nanoveu Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NVU, pending the release of an announcement regarding a new product..

07/04/2020

listed entity carried for record purposes only

03/12/2018

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    14/11/2019Steven Apedaile80,000$0.054$4,300
    27/09/2019Steven Apedaile150,000$0.050$7,500
    19/09/2019Alfred Chong20,000$0.045$900
    04/06/2019Steven Apedaile100,000$0.071$7,100
    06/03/2019Steven Apedaile100,000$0.083$8,300

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Alfred ChongExecutive Chairman, CEO30/11/2018
    Steven ApedaileNon Exec Director30/11/2018
    David NicolNon Exec Director30/11/2018
    Michael Van UffelenExecutive Director, CFO30/11/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION

    Date of first appointment, title may have changed.